Farma Mondo Group and KYAN Therapeutics sign exclusive partnership to commercialize OPTIM.AI in the MENA region

CHIASSO, Switzerland and SINGAPOREFebruary 6th, 2023 – Farma Mondo Group, a Swiss-based pharmaceutical group focused on providing market access and speciality distribution services through a unique infrastructure and geographical footprint across emerging and emerged markets, and Kyan Technologies Pte Ltd (“KYAN”) a biotechnology company redefining how therapies are offered to patients, announce today the signing of an exclusive marketing and distribution agreement in the MENA region for its OPTIM.AI platform, a revolutionary phenotypic response technology highly efficient in identifying safe and effective ​drug-dose combinations based on small inputs of data.

Under the terms of the agreement, Farma Mondo will manage the commercialization of OPTIM.AI in UAE, Kuwait, Oman, Qatar, KSA, Bahrain, Turkiye and Egypt.


Yaron Spigel, Group Chief Executive Officer of Farma Mondo, commented: we are proud to bring better and more advanced screening options for oncology patients in the MENAT region. Kyan is a promising technology company with innovative service for patients globally. FarmaMondo remains committed to bring health where no else does.


Hugo Saavedra, Chairman and CEO of KYAN said “KYAN is on a mission to bridge the cancer care gap by advancing revolutionary technologies. We are very fortunate to be working with Farma Mondo since they embrace this vision and see the potential bring our technology to help thousands of patients across the MENA region.”



KYAN’s approach is a truly personalized medicine solution that helps oncologists to provide cancer patients with the tailored treatments they really need.

It’s a unique and customized solution for each patient because the platform runs prospective experiments that measure the phenotypic response of drugs-doses based on the patient’s cancer cells.

The true power of OPTIM.AI lies on its Small Data AI, which is able to solve for thousands of clinically actionable regimens with a very small amount of patient sample.

All actionable treatments within a drug set are ranked and compared, including against standard care, to offer physician with the support needed when deciding how to treat each of their patients.


About Farma Mondo Group

Farma Mondo is a fast-growing Swiss group dedicated to providing Biopharma, healthcare professionals and their patients around the world with greater access to medicines, and in the process increasing the value of a pharmaceutical product by extending and expanding its lifecycle. The Group offers high value market access and specialty distribution services, through a unique infrastructure and geographical footprint, targeted to enable patient access to Specialty Medicines in key Emerging Markets through a combined approach of Named Patient access and full commercialization.

For more details, please visit

About Kyan Technologies Pte Ltd

KYAN Therapeutics is a biotechnology company on a mission to bridge the cancer care gap by advancing revolutionary technologies. Our technology has been developed and licensed from UCLA and the National University of Singapore (NUS). Optim.AI combines small data AI and biological experiments to define how therapies are developed and offered to patients.  From drug development to personalized medicine, KYAN offers an efficient solution to identify the optimal outcome to millions of possible drug-dose combinations.  KYAN’s research has multiple publications in several high impact journals like Nature Medicine, Science Translational Medicine, and Blood Cancer Journey.

For more details, please visit